For the Inventor, By the Inventor

Enter assignee name

Alameda, CA, United States of America

Glycomed, Inc.

USPTO Granted Patents = 56

Forward Citations = 1,416

Loading Chart...

Loading Chart...

54 inventors (with patents filed for the assignee):

John H Musser (23 out of 113 patents)

Brian K Brandley (14 out of 14 patents)

Narasinga Rao (12 out of 12 patents)

4. Mark Brian Anderson (11 out of 17 patents)

5. Kevin R Holme (10 out of 11 patents)

6. Michael Tiemeyer (10 out of 10 patents)

7. Falguni Dasgupta (8 out of 8 patents)

8. Daniel E Levy (7 out of 7 patents)

9. Peng Cho Tang (6 out of 118 patents)

10. Margaret Moreland (6 out of 17 patents)

11. Hans Schweingruber (6 out of 6 patents)

12. Stuart J Swiedler (6 out of 7 patents)

13. Saeed A Abbas (6 out of 6 patents)

14. Richard E Galardy (4 out of 9 patents)

15. Darwin S Asa (4 out of 4 patents)

Core Competencies:

Matrix Metalloprotease Inhibitors

Glycopeptides

Triterpenoid Derivatives

Oligosaccharides

Sialyl Lewis Compounds

Heparin Derivatives

Cell Adhesion Inhibitors

Anti-Inflammatory Agents

Sialic Acid

Fucose

Glycosides

Angiogenesis

56 patents: Sort by Forward Citations

1. 5892112 - Process for preparing synthetic matrix metalloprotease inhibitors (1999-04-06),

2. 5874411 - Oligosaccharide glycosides having mammalian immunosuppresive and (1999-02-23),

3. 5849709 - Saccharopeptides and derivatives thereof (1998-12-15),

4. 5837690 - Derivatives of triterpenoid acids and uses thereof. (1998-11-17),

5. 5837689 - Sialyl lewis-x mimetics containing naphthyl backbones (1998-11-17),

6. 5808021 - Method for controlling O-desulfation of heparin (1998-09-15),

7. 5795958 - Library of glyco-peptides useful for identification of cell adhesion (1998-08-18),

8. 5795875 - Therapeutic methods of using O-desulfated heparin derivatives (1998-08-18),

9. 5789385 - Sialyl Lewis.sup.x mimetics containing phenyl backbones (1998-08-04),

10. 5773438 - Synthetic matrix metalloprotease inhibitors and use thereof (1998-06-30),

11. 5763582 - Derivatives of triterpenoid acids and uses thereof (1998-06-09),

12. 5750508 - Sialic acid/fucose based medicaments (1998-05-12),

13. 5739115 - Sulfated maltooligosaccharides with heparin-like properties (1998-04-14),

14. 5728685 - Methods of treating inflammation using cell adhesion inhibitors (1998-03-17),

15. 5696147 - Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors (1997-12-09),

Glycomed, Inc., based in Alameda, California, specializes in glycobiology research, focusing on the development of innovative therapeutic agents. The company is recognized for its work with matrix metalloprotease inhibitors, glycopeptides, and triterpenoid derivatives, contributing to advancements in anti-inflammatory treatments and cell adhesion inhibition. Glycomed's research extends to oligosaccharides, sialyl Lewis compounds, and heparin derivatives, positioning it as a key player in the field of biopharmaceuticals and drug development.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

56 Patents

#11 in Alameda, CA

#1,490 in California

#6,346 in US

#12,732 in the World

Alameda, CA, United States of America

Glycomed, Inc.

Forward Citations = 1,416

54 inventors:

John H Musser (23 out of 113 patents)

Brian K Brandley (14 out of 14 patents)

Narasinga Rao (12 out of 12 patents)

4. Mark Brian Anderson (11 out of 17 patents)

5. Kevin R Holme (10 out of 11 patents)

Please report any incorrect information to [email protected]

Loading…